The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work ...
Although a start-up's recent triumph is seen as a 'DeepSeek moment', domestic players still trail world-beating pharma firms, experts say When Zhao Hong, chief doctor of China's leading cancer ...
Global harmonization of CMC guidelines is a key focus for top pharmaceutical consultants. Variations in regulatory requirements across regions often create inefficiencies in drug development—for ...
U.S. pharmaceutical company Eli Lilly plans to disclose the topline results of its phase 3 clinical trial for remternemab, a new drug candidate developed as a successor to its Alzheimer’s treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results